| Deliverable number | Deliverable name | Work package number | Short Name of lead participant | Dissemination level | Delivery date |
| D4.1 | Model selection process | WP4 | IMIM | CO | 28/02/2017 |
| D3.1 | Model compound and model selection process | WP3 | EMBL | CO | 31/03/2017 |
| D1.1 | Project Handbook | WP1 | SYNAPSE | CO | 30/04/2017 |
| D2.1 | Project communication plan and initial tool set | WP2 | SYNAPSE | CO | 30/06/2017 |
| D3.2 | Data management platform requirements documentation | WP3 | EMBL | CO | 30/06/2017 |
| D3.3 | Data integration and curation plan | WP3 | EMBL | CO | 30/06/2017 |
| D8.1 | Gap analysis and GI experimental plan | WP8 | UM | CO | 30/06/2017 |
| D2.2 | Data and Knowledge management plan | WP2 | SYNAPSE | CO | 30/09/2017 |
| D3.4 | Model compound selection | WP3 | EMBL | CO | 30/09/2017 |
| D4.2 | Criteria for continuation or cessation of specific model development | WP4 | IMIM | CO | 30/09/2017 |
| D3.5 | First release of the data management platform | WP3 | EMBL | CO | 31/12/2017 |
| D4.3 | Data models employed in downstream modelling methods | WP4 | IMIM | CO | 31/12/2017 |
| D6.1 | Datasets for DIKI | WP6 | EMBL | CO | 31/12/2017 |
| D7.1 | Report on modelling of potential anti-arrhythmogenic drugs on QTc prolongation and sudden cardiac death | WP7 | EMC | CO | 31/12/2017 |
| D4.4 | Biological pathways/modules relevant to build organ-specific dynamic models | WP4 | IMIM | CO | 30/04/2018 |
| D1.4 | Project assessment | WP1 | ULIV | CO | 31/12/2018 |
| D1.8 | Ethics workplan | WP1 | ULIV | CO | 31/12/2018 |
| D4.5 | First report on models developed on drug-organ toxicity events | WP4 | IMIM | CO | 31/12/2018 |
| D5.1 | Report on QST model for DILI with WGCNA approach | WP5 | ULIV | CO | 31/12/2018 |
| D5.2 | Report on QST model for DILI with GSMN approach | WP5 | ULIV | CO | 31/12/2018 |
| D7.2 | Report on modelling of glucose lowering drugs on stroke, MI, cardiovascular comorbidity | WP7 | EMC | CO | 31/12/2018 |
| D2.3 | Interim Report on dissemination activities | WP2 | SYNAPSE | CO | 30/06/2019 |
| D7.3 | Report on multiscale models | WP7 | UOXF | CO | 30/06/2019 |
| D1.9 | Ethics workplan. Update I | WP1 | ULIV | CO | 31/12/2019 |
| D3.6 | Second release of the data management platform | WP3 | EMBL | CO | 31/12/2019 |
| D7.4 | Report on the analysis of cardiotoxicity adverse outcomes pathways | WP7 | UOXF | CO | 31/12/2019 |
| D8.2 | PBPK-ADAM models expansion | WP8 | UM | CO | 31/12/2019 |
| D8.3 | Establishment of a characterised multi-cellular mouse/minipig/human organoid culture | WP8 | UM | CO | 31/12/2019 |
| D1.10 | Ethics Workplan. Update II | WP1 | ULIV | CO | 31/12/2020 |
| D3.7 | Report on data integration and curation | WP3 | EMBL | CO | 31/12/2020 |
| D4.6 | Second report on models on drug-organ toxicity events | WP4 | IMIM | CO | 31/12/2020 |
| D6.2 | Renal PBPK models including renal injury biomarkers | WP6 | SIMCYP | CO | 31/12/2020 |
| D3.8 | Final release of the data management platform | WP3 | EMBL | CO | 30/06/2021 |
| D4.7 | Workflows for the integration of modules and models for the description of drug-organ toxicity events | WP4 | IMIM | CO | 30/06/2021 |
| D4.9 | Omics data and analysis to support TransQST modelling | WP4 | IMIM | CO | 30/06/2021 |
| D6.3 | Quantitative co-regulated gene networks | WP6 | UL | CO | 30/11/2021 |
| D7.5 | Report on integration of PKPD modelling inpharmacoepidemiology | WP7 | EMC | CO | 31/12/2021 |
| D6.4 | Translational QST models for DIKI | WP6 | IMIM | CO | 30/04/2022 |
| D7.7 | Report on Translational Predictiveness | WP7 | UL | CO | 30/04/2022 |
| D2.4 | Final Report on dissemination activities | WP2 | SYNAPSE | CO | 30/06/2022 |
| D2.5 | Report on regulatory interactions | WP2 | SYNAPSE | CO | 30/06/2022 |
| D2.6 | Report on synergies with other initiatives | WP2 | SYNAPSE | CO | 30/06/2022 |
| D2.7 | Final Data and Knowledge management plan | WP2 | SYNAPSE | CO | 30/06/2022 |
| D3.9 | Sustainability plan for models, data, and infrastructure | WP3 | EMBL | CO | 30/06/2022 |
| D4.8 | Publication describing the entire modelling approach | WP4 | IMIM | CO | 30/06/2022 |
| D5.3 | Report for mechanistic simulation | WP5 | ULIV | CO | 30/06/2022 |
| D6.5 | Novel assays for modelling QST | WP6 | UL | CO | 30/06/2022 |
| D6.6 | Application of renal translational QST models using pharma relevant drug compounds | WP6 | UL | CO | 30/06/2022 |
| D6.7 | Report on preservation of rat liver/kidney WGCNA networks in human tissue | WP6 | UL | CO | 30/06/2022 |
| D7.6 | Model Development Report | WP7 | UL | CO | 30/06/2022 |
| D7.8 | White paper on role of QST models in earlier recognition of potential adverse drug reactions | WP7 | EMC | CO | 30/06/2022 |
| D7.9 | Report on modelling of Snelder model in real life | WP7 | EMC | CO | 30/06/2022 |
| D7.10 | A proposal for qualification of the cardiac in silico biomarkers as a proarrhythmia model prepared for submission to a regularoty agency model qualification group | WP7 | UOXF | CO | 30/06/2022 |
| D8.4 | Report on transcriptomic and functional data on dynamic intestinal toxicity | WP8 | UM | CO | 30/06/2022 |
| D8.5 | Report on multi-scale model for drug-induced and acute inflammation-mediated intestinal toxicity | WP8 | UM | CO | 30/06/2022 |
| D1.11 | Final Ethics report | WP1 | ULIV | CO | 31/08/2022 |
